ReviewFrontiers in immunology2025
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- p300: expanding beyond acetylation to mastermind lactylation-dependent tumorigenesis.Frontiers in cell and developmental biology · 2026Review
- Molecular screening of natural compounds targeting KRAS(G12C): a multi-parametric strategy against acute lymphoblastic leukemia.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma is a highly heterogeneous hematologic malignancy characterized by intricate molecular and pathological mechanisms. Key mechanisms contributing to its complexity include malignant clonal evolution driven by somatic mutations, epigenetic modifications affecting gene regulation and cellular behavior, and dynamic tumor microenvironment remodeling. These factors collectively undermine the efficacy of conventional therapeutic strategies. Differences in the molecular mechanisms of different subtypes lead to heterogeneity in treatment response and recurrence of drug resistance. Current and future investigative priorities emphasize molecular stratification, precision diagnosis and therapeutic strategies, advancement of novel diagnostic tools, and the implementation of artificial intelligence (AI) for integrative analysis of high-dimensional biological data. Moreover, emerging areas such as microbiome-targeted interventions are being explored to improve clinical outcomes and support the evolution of precision oncology in lymphoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.